E-DRUG: Therapeutics Letter #61: What is the Common Drug Review?
-------------------------------------------------------------
NEW: THERAPEUTICS LETTER #61(Oct-Dec 2006): "What is the Common Drug Review":
http://www.ti.ubc.ca/pages/letter61.htm
I would like to bring to your attention the latest issue (#61) of the Therapeutics Letter: "What is the Common Drug Review?" that has just been posted on the Therapeutics Initiative web site at
http://www.ti.ubc.ca/pages/letter61.htm
In this Therapeutics Letter we introduce Canada's Common Drug Review (CDR), a standardized process of reviewing the relative therapeutic and cost effectiveness of new brand name drugs in Canada. In this Letter we also provide summaries of 4 CDR recommendations: Pregabalin (Lyrica®) for management of neuropathic pain; Atomoxetine (Strattera®) for the treatment of attention deficit hyperactivity disorder (ADHD); Ciclesonide (Alvesco®) for prophylactic management of steroid-responsive bronchial asthma; Teriparatide (Forteo®) for treatment of postmenopausal women with severe osteoporosis and men with primary or hypogonadal severe osteoporosis.
I invite you to drop by and have a look at this Letter. Please feel free to forward this message to any of your friends or colleagues that might be interested in this topic.
We would appreciate receiving your comments on this Therapeutics Letter and its possible implications in clinical practice.
Regards,
Ciprian Jauca
Manager
Therapeutics Initiative
University of British Columbia
Department of Anesthesiology, Pharmacology & Therapeutics
2176 Health Sciences Mall
Vancouver, BC V6T 1Z3
Canada
Tel: +1-604-822-0700
Fax: +1-604-822-0701
Web: www.ti.ubc.ca
Email: jauca@ti.ubc.ca